LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
Q3 2024 Trading Update (Unaudited)
Ballerup, Denmark, 31 October, 2024 - In the first nine months of 2024, LEO Pharma delivered revenue growth of 11% in constant exchange rates (CER). The dermatology portfolio saw revenue growth of 13%. Significant strategic progress was highlighted by several key events around the globe: the European Commission’s approval of Anzupgo® (delgocitinib) cream for adults with moderate to severe chronic hand eczema (CHE), the filing of a New Drug Application (NDA) for delgocitinib cream with the Food and Drug Administration (FDA) in the U.S., and the filing of an NDA for Enstilar® for adults with plaque psoriasis in China. Full-year outlook remains unchanged.
"We are very satisfied with the sales growth in the first nine months of 2024, reflecting that more people than ever are benefiting from our treatments. At the same time, we have taken significant steps toward commercializing Anzupgo® (delgocitinib), securing European approval and launching it in its first European markets. Notably, we have filed for its approval in the U.S., marking a major milestone. Along with the recent filing of Enstilar in China, we are cementing our worldwide presence and transforming LEO Pharma into a truly global company,” says CEO Christophe Bourdon.
Q3 2024 financial highlights
- Revenue grew 10% (CER) to DKK 3,057 million (Q3 2023: DKK 2,791 million). Reported growth was 10%.
- Dermatology revenue grew 12% (CER) to DKK 2,479 million (Q3 2023: DKK 2,230 million), driven by solid growth of Adtralza®/Adbry® (tralokinumab) for atopic dermatitis (AD).
- Adtralza®/Adbry® revenue increased by 70% (CER) driven by continued uptake across markets, especially in North America.
- Growth across all regions: North America up 34%, Europe up 6%, Rest of the World up 4% (CER). North America continues to be the key growth driver with revenue of DKK 610 million (Q3 2023: DKK 458 million).
- Thrombosis revenue increased by 6% (CER) driven by sales across European markets.
- In the first nine months, total revenue was up 11% in CER at DKK 9,432 million (9M 2023: DKK 8,589 million), while dermatology revenue was up 13% (CER) at DKK 7,580 million (9M 2023: DKK 6,806 million). Within dermatology, key growth drivers include Adtralza®/Adbry® and solid growth within the core dermatology portfolio, led by Protopic and Enstilar.
- Full-year outlook remains unchanged.
Progress on strategic priorities
- European Commission’s approval of delgocitinib cream for adults with moderate to severe chronic hand eczema (CHE).
- Commercialization of delgocitinib cream began with its initial launches in Germany and Denmark in October under the brand name Anzupgo®.
- Ramp-up in U.S. business accelerated by the Food and Drug Administration’s (FDA) filing acceptance of a New Drug Application (NDA) for delgocitinib cream to treat CHE and launch of Adbry autoinjector for atopic dermatitis (AD) treatment
- Prioritizing opportunities for further expanding impact of delgocitinib, including indication expansion, re-formulation and combinations.
- NDA for Enstilar® for adults with plaque psoriasis submitted in China.
- Most extensive LEO Pharma program to date at the European Academy of Dermatology and Venereology (EADV) congress featured an industry-high of five late-breaking abstracts and 23 posters sharing clinical and real-world data, with highlights including:
- DELTA FORCE trial data demonstrating that topical treatment with delgocitinib cream had a significantly higher efficacy compared to an oral (systemic) treatment among adult patients with severe CHE;
- Nine-month interim data from the TRACE study, showing that tralokinumab reduced the severity of moderate-to-severe AD in the head and neck region of the body;
- Phase 2A data comparing clinical and molecular responses in the targeting of IL-22RA1 with temtokibart vs dupilumab in patients with moderate to severe AD.
- Decision to implement prioritization initiatives in 2024 to free up resources and support the earnings ambitions going forward. Up to 250 positions estimated to be impacted.
- Commitment to achieving net-zero emissions by 2050, with a decarbonization plan aligned with the Paris Agreement and climate science to limit global warming to 1.5˚C.
Forward-looking statements
This announcement contains forward-looking statements, including forecasts of future revenue and operating profit, as well as expected business-related events. Such statements are subject to risks and uncertainties, as various factors, some of which are beyond LEO Pharma’s control, may cause actual results and performance to differ materially from the forecasts made in this announcement.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, mobile +45 3050 2014
Vedhæftede filer
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of approx. 4,000 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma lancerer Anzupgo® (delgocitinib) creme i hjemmemarkedet Danmark som det andet land i verden28.10.2024 12:00:00 CET | Pressemeddelelse
Efter Europa Kommissionens produktgodkendelse i september bliver Danmark det næste og kun andet land i verden, hvor LEO Pharma lancerer sit nyeste lægemiddel, Anzupgo® (delgocitinib) creme, efter lanceringen i Tyskland tidligere på måneden. (1) Anzupgo® creme er den første godkendte topikale behandling for voksne med moderat til svært kronisk håndeksem, hvor topikale kortikosteroider er utilstrækkelige eller uhensigtsmæssige. (1) Lanceringen giver en ny behandlingsmulighed for de mange voksne danskere, som lever med moderat til svært kronisk håndeksem, som er en af de mest udbredte kroniske inflammatoriske hudsygdomme, der rammer 4,7% af befolkningen. (2,3)
Germany Becomes the First Country to Launch LEO Pharma’s Anzupgo® (delgocitinib) Cream15.10.2024 09:00:00 CEST | Pressemeddelelse
Following the recent European Commission (EC) approval, Germany has become the first country worldwide where Anzupgo will be made available.(1) Anzupgo is the first topical treatment specifically indicated for adults with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.(1) The launch brings a new treatment option for the estimated 3.9 million people in Germany living with CHE, a condition with a high unmet need for which no specifically approved topical treatment was previously available.(2,3)
LEO Pharma commits to net-zero greenhouse gas emissions by 205011.10.2024 11:00:00 CEST | Pressemeddelelse
A net-zero target is a natural continuation of our current commitments to run a sustainable business, LEO Pharma says.
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD) in the Difficult-to-Treat Head and Neck Region27.9.2024 15:00:00 CEST | Pressemeddelelse
Real-world findings showed that subgroup of patients treated with Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) and with head and neck (H&N) atopic dermatitis (AD) at baseline reported presence of AD in that area in 52.1% of patients after nine months of treatment.(1) As part of one of LEO Pharma’s most extensive scientific programs at EADV to date, the late-breaking presentation examined interim data from the real-world TRACE study of adult AD patients who have been prescribed Adtralza/Adbry for up to nine months.(1) Additional posters presented interim results of the TRACE study on effectiveness of Adtralza/Adbry treatment through various physician and patient reported outcomes such as improvements in Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), itch, sleep disturbance and quality of life.(2,3)
LEO Pharma submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China27.9.2024 12:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Enstilar® (LEO 90100) to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA). The NDA is supported by results from a phase 3 trial comparing the efficacy and safety of Enstilar with Daivobet® ointment in adult Chinese patients.(1,2) The Enstilar submission demonstrates LEO Pharma's commitment to providing additional treatment options for the estimated seven million adult patients living with plaque psoriasis in China.(3)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum